ANI Pharmaceuticals Inc
corporate_fare Company Profile
ANI Pharmaceuticals Inc (NASDAQ:ANIP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for ANIP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 9/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for ANIP spans 8-K, 10-Q, 4, 144.
Recent high-impact activity:
- ANI Launches ~$560M Cash Offer for Egetis, Backed by $676M JPMorgan Bridge Facility
- ANI Q3 10-Q: $290.8M Revenue, $35.1M Net Income, $420.8M Cash, $676M Egetis Bridge
- ANI Q3 Beats at $2.70 EPS, Cuts Cortrophin Guidance, Launches ~$560M Egetis Offer
- ANI Pharmaceuticals Posts 3Q Adjusted EPS of $2.70
- ANI Pharma Offers to Buy Sweden's Egetis Therapeutics to Bolster Rare Disease Franchise
Financial Snapshot
Short Interest & Short Volume
11.88 days to coverFINRA reported short interest of 3,583,674 shares in ANIP as of the October 30, 2026 settlement, a 3.2% increase from the prior period — about 11.9 days to cover at its recent average daily volume. On November 20, 2026, 64.6% of ANIP volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.